Novartis Pharma AG is the pharmaceutical subsidiary of Novartis AG that makes strategic corporate venture investments in life science companies. It invests through vehicles including the Novartis Venture Fund (NVF) and dRx Capital, managing approximately USD 750 million in committed capital across over 40 portfolio companies in biotechnology and biopharmaceuticals.
54% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (4 deals in the last 12 months). Average disclosed round size is $71.9M (across 29 rounds with reported amounts).
Portfolio
31
Fund Size
—
Top Stage
Series A
Last 12 Mo
4
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
35 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 EpiBiologics | Series B | — | Jan 2026 |
 FoRx Therapeutics | Series A | $50M | Dec 2025 |
 Flywheel | Series B | $27.5M | Dec 2025 |
 Artios Pharma | Series D | $115M | Nov 2025 |
 SpliceBio | Series B | $135M | Jun 2025 |
 Citryll | Series B | — | Dec 2024 |
| EExsilio Therapeutics | Series A | $82M | Jun 2024 |
 AstronautX | Series A | $61M | Oct 2023 |
 Tagworks Pharmaceuticals | Series A | $65M | Jun 2023 |
 Flare Therapeutics | Series B | $123M | Mar 2023 |
| AAlladapt Immunotherapeutics Inc. | Unknown | $119M | Jun 2022 |
| SpliceBio | Series A | — | Feb 2022 |
 Koneksa Health | Series C | $45M | Feb 2022 |
| IImmPACT Bio USA | Series B | $111M | Jan 2022 |
 Freenome Inc | Series D | $300M | Dec 2021 |
| Artios Pharma | Series C | $153M | Jul 2021 |
 Nuvoair | Series A | $12M | Jun 2021 |
| SSoteria Biotherapeutics | Series A | $42M | May 2021 |
 Aktis Oncology | Series A | $72M | Mar 2021 |
 Science 37 | Series B | $40M | Aug 2020 |
| IImmPACT Bio USA | Series A | $18M | Aug 2020 |
 GentiBio | Seed | $20M | Aug 2020 |
 Vineti | Series C | $35M | Feb 2020 |
| SSiO2 Medical Products | Unknown | — | Nov 2019 |
 Xealth | Series A | $11M | Mar 2019 |
Page 1 of 2
Top Co-Investors
EQT Life Sciences6 shared
Pfizer Ventures6 shared
GV5 shared
The Invus Group, LLC5 shared
M Ventures5 shared
Ysios Capital4 shared
OrbiMed4 shared
Roche Venture Fund4 shared
MPM Capital3 shared
New Enterprise Associates3 shared
Gilde Healthcare3 shared
Andera Partners3 shared
SV Health Investors3 shared
IP Group plc3 shared
RA Capital Management3 shared
Bristol Myers Squibb3 shared
Casdin Capital2 shared
S322 shared
Threshold Ventures2 shared
Polaris Partners2 shared
Last updated: 8 September 2026